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ABSTRACT
Objective: Treatment of subclinical hypothyroidism (ScH), especially the mild form of ScH, is 
controversial because thyroid hormones influence cardiac function. We investigate left ventricular 
systolic and diastolic function in ScH and evaluate the effect of 5-month levothyroxine treatment. 
Subjects and methods: Fifty-four patients with newly diagnosed mild ScH (4.2 < TSH < 10.0 mU/L) and 
30 euthyroid subjects matched by age were analysed. Laboratory analyses and an echocardiography 
study were done at the first visit and after 5 months in euthyroid stage in patients with ScH. Results: 
Compared to healthy controls, patients with ScH had a lower E/A ratio (1.03 ± 0.29 vs. 1.26 ± 0.36, p < 
0.01), higher E/e’ sep. ratio (7.62 ± 2.29 vs. 6.04 ± 1.64, p < 0.01), higher myocardial performance index 
(MPI) (0.47 ± 0.08 vs. 0.43 ± 0.07, p < 0.05), lower global longitudinal strain (GLS) (-19.5 ± 2.3 vs. -20.9 ± 
1.7%, p < 0.05), and lower S wave derived by tissue Doppler imaging (0.077 ± 0.013 vs. 0.092 ± 0.011 m/s, 
p < 0.01). Levothyroxine treatment in patients with ScH contributed to higher EF (62.9 ± 3.9 vs. 61.6 ± 
4.4%, p < 0.05), lower E/e’ sep. ratio (6.60 ± 2.06 vs. 7.62 ± 2.29, p < 0.01), lower MPI (0.43 ± 0.07 vs. 0.47 ± 
0.08%, p < 0.01), and improved GLS (-20.07 ± 2.7 vs. -19.55 ± 2.3%, p < 0.05) compared to values in ScH 
patients at baseline. Furthermore, in all study populations (ScH patients before and after levothyroxine 
therapy and controls), TSH levels significantly negatively correlated with EF (r = -0.15, p < 0.05), E/A (r 
= -0.14, p < 0.05), GLS (r = -0.26, p < 0.001), and S/TDI (r = -0.22, p < 0.01) and positively correlated with 
E/e’ sep. (r = 0.14, p < 0.05). Conclusion: Patients with subclinical hypothyroidism versus healthy 
individuals had subtle changes in certain parameters that indicate involvement of systolic and 
diastolic function of the left ventricle. Although the values of the parameters were in normal range, 
they were significantly different compared to ScH and the control group at baseline, as well as to the 
ScH groups before and after treatment. The results of our study suggest that patients with ScH must be 
followed up during treatment to assess improvement of the disease. Some of the echocardiography 
obtained parameters were reversible after levothyroxine therapy. Arch Endocrinol Metab. 2018;62(4):392-8
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INTRODUCTION
S ubclinical hypothyroidism (ScH) is defined as a condition with a slight increase in serum 
concentration of thyrotropin (TSH) with normal values 
of circulating thyroid hormones, free thyroxine (FT4) 
and triiodothyronine (FT3).
The upper limit of TSH from which thyroid 
replacement therapy should start is still a topic of 
debate (1,2). Treatment is generally recommended in 
severe ScH (TSH value above 10 mU/L) (2-6). When 
the TSH value is less than 10 mU/L, treatment may 
be indicated in relation to age, presence of goiter, or 
antithyroid antibodies. One meta-analysis (7) proposed 
starting with thyroid replacement therapy when TSH 
levels are above 7 mU/L. Previous research (8) showed 
increased risk of atherosclerosis in patients with ScH at 
levels above 7 mU/L. 
Thyroid hormones influence cardiac function 
(9,10). They regulate the transcription of structural and 
regulatory proteins in the cardiovascular system (11), 
predispose chronic inflammation and tissue changes 
(collagen alteration, dehydration), and also cause 
hemodynamic changes through their effect on smooth 
muscles in the arterial wall (10,12). All these can alter 
cardiac function and together with atherosclerosis 
increase the risk of cardiovascular manifestations. 
Research has revealed that substitution therapy with 
levothyroxine in ScH with TSH values above 10 mU/L 
could improve left ventricular (LV) function (13-16). 
Whether the same is true for mild ScH (TSH values less 
than 10 mU/L) is unknown.
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The aim of the study was to evaluate the effect 
of levothyroxine therapy on LV systolic and diastolic 
function in patients with a mild form of ScH (4.2 < 
TSH < 10.0 mU/L) and after 5 months in euthyroid 
stage, using two-dimensional echocardiography, pulse 
Doppler, tissue Doppler, and two-dimensional speckle 
tracking imaging. An additional aim of the study was to 
predict which parameters derived by echocardiography 
can be used to monitor patients with ScH.
SUBJECTS AND METHODS
Patients
The prospective study was conducted at the University 
Clinic of Endocrinology and the University Clinic of 
Cardiology in Skopje, R. Macedonia. The study included 
a control group and patients with a newly diagnosed mild 
form of ScH. The control group consisted of 30 healthy 
euthyroid patients (normal FT4, FT3, and TSH of 0.2–
4.2 mU/L). The criteria for a diagnosis of mild ScH were 
4.2 mU/L < TSH < 10.0 mU/L with normal serum 
FT4 10.3–24.45 pmol/L and FT3 4.2–8.1 pmol/L. 
According to the recommendations of the British 
Thyroid Association, patients with ScH were placed 
on thyroid replacement therapy if one of the following 
criteria were present: at least three signs or symptoms 
of hypothyroidism, positive anti-TPO antibodies and 
positive anti-Tg antibodies, positive family history of 
thyroid disease, and thyroid enlargement or goiter on 
ultrasonography (17). The starting dose of L-thyroxine 
was 25 μg. TSH was measured every 8 weeks for dose 
adjustment. After 5 months in continuous euthyroid 
state, echocardiography was repeated. The euthyroid 
state was achieved with a mean dose of 60.8 ± 19 μg 
in mean duration of 7.5 ± 2.2 months. During a period 
of three years, 54 consecutive patients were included in 
the ScH group. 
The control group was included to compare 
echocardiography parameters from the mild form of 
SCH at baseline. 
Exclusion criteria
Patients with a previous history of thyroid disease 
receiving therapy for thyroid or cardiovascular function 
were not included. Patients who were cigarette smokers 
or who had cardiovascular disease, hypertension, 
hypothalamic-pituitary disease, depression, psychosis, 
bipolar disorders, diabetes, chronic pancreatitis, hepatic 
or renal disease, ovulatory dysfunction, infertility, or 
pregnancy were also not included.
Ethical aspects
All patients gave informed consent to participate in the 
study after careful explanation of the testing protocol. The 
study was conducted in accordance with the Declaration 
of Helsinki and approved by the Ethics Committee at 
the Medical Faculty in Skopje, R. Macedonia.
METHODS
At the first visit to the University Clinic of 
Endocrinology, blood samples for TSH, FT4, and 
FT3 were taken from all patients. At the same time, 
at the Outpatient Department of Cardiology Clinic, 
transthoracic echocardiography was done. Two-
dimensional (2D) echocardiography, pulsed wave 
(PW) Doppler, tissue Doppler imaging (TDI), and 2D 
speckle tracking echocardiography were used to assess 
left ventricular systolic and diastolic function.
Laboratory tests
All blood samples for thyroid hormones were collected 
from the antecubital vein between 08.00 and 09.00 
a.m. TSH, FT4, and FT3 were determined by the super-
sensitive chemiluminescent immunoassay (Immulite 
2000, Siemens Medical Solutions Diagnostics, Los 
Angeles, CA, USA). The functional sensitivity for 
TSH was 0.004 μIU/mL, for FT4 0.3 ng/dL, and 
FT3 0.4 ng/dL.
Echocardiographic measurements
Standard assessments of LV dimensions and wall 
thickness were performed in standard views on 
commercially available equipment (Vivid 7, GE) 
according to the joint recommendations of the 
American Society of Echocardiography and the 
European Association of Cardiovascular Imaging 
(18). LV volume and ejection fraction were calculated 
using the biplane method of disks (modified Simpson’s 
rule). Left atrial volume was derived by the biapical 
area-length method and indexed to body surface area 
(LAVI) (18). Diastolic parameters were obtained by 
pulsed Doppler by placing a sample volume at the 
point of touching the mitral leaflets: early mitral flow 
(E wave, in m/s) and late mitral flow (A wave, m/s), 
their ratio (E/A, m/s), and deceleration time (DT, 
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msec). Pulmonary venous flow was analysed using 
PW Doppler. We estimate peak systolic flow (S wave, 
m/s), early diastolic flow (d wave, m/s), s/d ratio, and 
atrial reversal flow (Ar, m/s), including Ar-A duration 
(msec) difference (19). PW TDI was performed in the 
apical 4-chamber view to assess annular early and late 
diastolic velocities (19). The recording was performed 
at a sweep speed of 100 mm/s at end-expiratory apnea. 
The septal, lateral, and average early diastolic velocities 
were measured, then the ratio of mitral flow E wave and 
TDI e’ wave (E/e’) for each of these annular velocities 
was calculated. By TDI we also estimate S wave like a 
maximal systolic velocity (m/sec) which is a parameter 
for evaluation of longitudinal systolic function (20). 
With the values of isovolumetric contractile time 
(IVCT, msec), isovolumetric relaxation time (IVRT, 
msec), and ejection time (ET, msec) derived by TDI, 
we calculated the myocardial performance index (MPI), 
which is a parameter for global left systolic function. 
We use the formula MPI = IVCT + IVRT / ET. The 
average of three consecutive cardiac cycles was taken 
for measurement of each echocardiographic index.
Global and regional peak systolic longitudinal 
strain was assessed from apical 2-chamber, 4-chamber, 
and long-axis views using speckle tracking analysis 
(21). Recordings were processed using an acoustic 
tracking software (EchoPac, GE, USA), allowing 
offline semiautomated analysis of speckle-based strain. 
All images were recorded with a high frame rate (> 50 
frames/s). A semiautomatic myocardial tracking system 
was used, with manual correction of the endocardial 
border in end-systole and manual adjustment of the 
region of interest, if needed. The end of systole was 
defined as the point of aortic valve closure. The software 
automatically detected the frame-to-frame movement 
of the natural ultrasound reflecting markers (speckles) 
on standard ultrasonic images in two dimensions. The 
LV was divided into 17 segments, and each segment 
was analysed individually. Only myocardial segments 
considered to be of adequate quality by both the 
automatic system and the operator were included 
in the analysis. Global longitudinal strain for the LV 
was automatically provided as the average value of the 
regional peak systolic longitudinal strain of the three 
apical views by the software.
Statistical analysis
Categorical parameters were summarized as percentages 
and continuous parameters as mean ± SD. The normal 
distribution of variables was verified with the Shapiro-
Wilk test. As the distribution was normal, Student’s 
independent t-test was used for the comparison of 
the quantitative data between the control group and 
the ScH group at baseline. Student’s paired t-test was 
used for the comparison of the quantitative data before 
and after the levothyroxine therapy in the ScH group. 
For the comparison of categorical variables the chi-
square test, Yates correction was used. The correlation 
between the tested parameters was determined using 
the Pearson correlation. All data analysis was performed 
using SPSS version 14.0 (IBM SPSS, Inc., Chicago, 
Illinois) and p value ≤ 0.05 was considered significant.
RESULTS
Patients and normal controls were well matched for 
age, sex, BMI, and BSA. Heart rate was similar in both 
groups, but significantly increased in the ScH group 
after the levothyroxine treatment. The systolic blood 
pressure was significantly higher in the ScH group at 
baseline than in the control group, but the treatment 
with levothyroxine didn’t make any changes. The 
diastolic blood pressure was similar in both groups, 
without difference after levothyroxine treatment. 
As expected, TSH levels were significantly higher in 
the ScH group than in the control group. FT4 and 
FT3 levels, although in the reference range, were 
significantly lower in the ScH group at baseline than 
in the control group. Interestingly, after the thyroid 
substitution therapy, FT4 and FT3 levels significantly 
increased in the ScH group (Table 1). 
The LV diameters and volumes were similar in both 
groups, ScH at baseline and control groups. Overall, 
only EF (although in referent range in all analysed 
groups) statistically significantly increased in the ScH 
group after the levothyroxine therapy (Table 2).
The results from echocardiography (systolic and 
diastolic parameters) in all analysed groups were in 
normal range, but some of them were statistically 
different compared to ScH and the control group at 
baseline, as well as to the ScH groups before and after 
treatment. The transmitral E/A ratio was lower and E/e’ 
sep. ratio was higher in the ScH group at baseline than 
in the control group. The E/e’ sep. ratio significantly 
decreased in the ScH group after levothyroxine therapy. 
The MPI was higher in the ScH group at baseline 
than in the control group and significantly decreased 
after levothyroxine therapy. The GLS was significantly 
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reduced in the ScH group at baseline in comparison 
to the control group and significantly improved after 
levothyroxine therapy. The S wave estimated from TDI 
was significantly lower in the ScH group at baseline 
Table 1. Demographic, clinical, and hormonal parameters of study population
  Control group (n = 30) Baseline ScH (n = 54) ScH after 5 months (n = 54) Statistical significance
Age (years) 39.3 ± 11.7 43.1±12.4 NS
Sex (m:f) 3 : 27 (10%) 2.52 (3.7%) NS
BMI (kg/m2) 24.3 ± 3.0 26.7 ± 4.2 25.7 ± 4.2 NS
BSA (m2) 1.78 ± 0.15 1.79 ± 0.17 1.78 ± 0.16 NS
HR (bpm) 76.4 ± 9.1 73.4 ± 9.8 77.1 ± 9.9 p < 0.05b
Systolic BP (mmHg) 107.3 ± 28.4 123.3 ± 16.4 122.1 ± 14.2 p < 0.05a,c
Diastolic BP (mmHg) 77 ± 13.4 80.0 ± 9.3 79.2 ± 8.4 NS
TSH mU/L 1.7 ± 1.05 8.1 ± 1.3 2.8 ± 2.6 p< 0.001a,b
FT4 pmol/L 15.4 ± 2.2 12.3 ± 2.0 15.2 ± 2.6 p < 0.01a,b
FT3 pmol/L 5.2 ± 2.1 4.5 ± 1.1 6.4 ± 3.3 p < 0.05a,b
Displayed results are average ± std deviation and percentages. Comparisons between the groups were performed by Student’s t-test (independent and dependent) for continuous variables and χ2 
test for categorical variables. 
a Statistical significance for controls vs. baseline ScH; b statistical significance for baseline ScH vs. ScH after 5 months; c statistical significance for controls vs. ScH after 5 months.
BMI: body mass index; BSA: body surface area; HR: heart rate; BP: blood pressure; NS: no significance.
Table 2. Echocardiographic parameters of left ventricular function in the study population
  Control group (n = 30) Baseline ScH (n = 54) ScH after 5 months (n = 54) Statistical significance
LA (mm) 31.7 ± 3.1 31.3 ± 3.9 31.7 ± 3.9 NS
LAVI (ml/m2) 24.4 ± 4.31 21.9 ± 5.77 20.7 ± 5.43 NS
LVEDD (mm) 46.0 ± 4.8 46.4 ± 4.3 45.6 ± 4.1 NS
LVED vol (mL3) 79.1 ± 11.9 81.7 ± 18.4 79.0 ± 18.6 NS
LVES vol (mL3) 31.3 ± 7.0 31.6 ± 7.8 30.6 ± 6.5 NS
EF (%) 62.8 ± 2.3 61.6 ± 4.4 62.9 ± 3.9 p < 0.05b
IVS (mm) 10.4 ± 1.1 10.8 ± 0.9 10.8 ± 1.0 NS
PW (mm) 8.7 ± 1.2 8.7 ± 1.2 8.7 ± 1.1 NS
E/A (m/sec) 1.26 ± 0.36 1.03 ± 0.29 1.09 ± 0.34 p < 0.01a,c
DT(msec) 156.8 ± 29.7 167.9 ± 38.6 158.5 ± 32.2 NS
E/e’ sep. 6.04 ± 1.64 7.62 ± 2.29 6.60 ± 2.06 p < 0.01a,b
E/e’ lat. 6.08 ± 1.24 6.35 ± 1.62 6.03 ± 1.74 NS
E/e’ average 6.06 ± 1.24 6.98 ± 1.9 6.74 ± 1.7 NS
IVCT (msec) 60.04 ± 10.9 64.14 ± 13.4 60.29 ± 12.7 NS
IVRT (msec) 66.39 ± 8.3 67.27 ± 13.7 65.0 ± 12.8 NS
MPI 0.43 ± 0.07 0.47 ± 0.08 0.43 ± 0.07 p < 0.05a; p < 0.01b
s/d 1.26 ± 0.11 1.26 ± 0.16 1.25 ± 0.22 NS
GLS (%) -20.9 ± 1.7 -19.55 ± 2.3 -20.07 ± 2.7 p < 0.001a; p < 0.05b
S/TDI (m/sec) 0.092 ± 0.011 0.077 ± 0.013 0.078 ± 0.01 p < 0.01a,c
Ar-A -18.87 ± 10.78 -25.2 ± 16.1 -23.4 ± 9.1 NS
Displayed results are average ± std deviation and percentages. Comparisons between the groups were performed by Student’s t-test (independent and dependent) for continuous variables and χ2 
test for categorical variables. 
a Statistical significance for controls vs. baseline ScH; b Statistical significance for baseline ScH vs. ScH after 5 months; c statistical significance for controls vs. ScH after 5 months.
LA: left atrial systolic diameter; LAVI: left atrial volume index; LVEDD: end-diastolic diameters; PW: the left ventricular posterior wall; IVS: interventricular septum thickness; LVESV: left ventricular 
end-systolic volume; LVEDV: left ventricular end-diastolic volume; EF: ejection fraction; E/A: ratio between transmitral early and late diastolic peak flow velocities; A dur: duration of the atrial 
contraction; DT: time between E velocity deceleration time to the baseline; S wave obtained by TDI, maximal systolic flow velocity; IVCT: isovolumetric contraction time; IVRT: isovolumetric relaxation 
time; MPI: myocardial performance index; s: systolic velocity of the pulmonary veins; d: diastolic velocity of the pulmonary veins; their ratio (s/d); Ar: retrograde pulmonary venous flow during the 
atrial contraction–atrial reversal; A-Ar: difference in time of duration of the A wave from transmitral flow by PW and duration of the Ar wave from pulmonary vein flow; GLS: global longitudinal strain.
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than in the control group, without changes after the 
levothyroxine therapy (Table 2). Analysing how many 
patients had diastolic dysfunction, according to new 
guidelines for the evaluation of diastolic function by 
echocardiography, showed that there were only three 
patients with ScH (22). In all three patients diastolic 
dysfunction was reversible after thyroid replacement 
therapy. 
Considering the entire study population, the 
TSH levels (before and after levothyroxine therapy) 
significantly negatively correlated with EF (r = -0.15, 
p < 0.05), E/A ratio (r = -0.14, p < 0.05), GLS (r = 
-0.26, p < 0.001), and S/TDI (r = -0.22, p < 0.01) 
and positively correlated with E/e’ sep. (r = 0.14, p < 
0.05). 
DISCUSSION 
The results of the study presented subtle changes in the 
LV systolic and diastolic function which were reversible 
after thyroid replacement therapy. Although the values 
of the echocardiography parameters were in normal 
range in all analysed groups (control, ScH at baseline, 
and SCH after treatment), there were statistically 
significant differences between some parameters 
compared to the control and ScH group at baseline, 
as well as to the ScH group before and after treatment. 
Our results show that the ScH group at baseline had 
statistically significantly higher values  for systolic blood 
pressure. This result is similar to the results in one 
meta-analysis published in 2014. The study includes 
the analysis of 20 studies and found a slight increase 
in systolic blood pressure in patients with ScH versus 
the control group (23). Systolic blood pressure did not 
decrease significantly after the levothyroxine treatment. 
The average value for systolic blood pressure in the ScH 
group at baseline was normal (123.3 ± 16.4 mmHg), 
so the thyroid replacement therapy probably had no 
clinical significance in reducing its value. Thus, we can 
conclude that ScH had no significant impact on the 
arterial blood pressure, in contrast to what is already 
known about clinical hypothyroidism. Therefore, 
we do not expect the thyroid replacement therapy to 
significantly decrease the already normal values for 
systolic blood pressure.
Heart rate statistically significantly increased 
after thyroid replacement therapy. These changes 
are consistent with the known mechanism of action 
of thyroid hormones. From a clinical point of view, 
the increase in heart rate after treatment was still in 
the normal range (77.1 ± 9.9 minute), but there 
was statistical significance. None of the patients after 
treatment had tachycardia or arrhythmia.
At baseline, echocardiographic parameters of LV 
function were not significantly different between the 
control and the ScH group, which were similar with 
results from other studies (15,24-28). Five months of 
levothyroxine therapy statistically significantly increased 
the EF. Only a small (1.3%) increase in EF was sufficient 
to make EF equal to the value (62.9 ± 3.9%) as in the 
control group. In the study of Ilic and cols. (29), one-
year therapy with levothyroxine showed results similar 
to ours. It is important to mention that all studies 
(including ours) that analyse the EF in patients with 
ScH have normal values for EF. 
The parameter S derived from TDI, which is a 
parameter to assess systolic function of LV, was statistically 
significantly lower in the ScH group compared to the 
control group. This proves the abnormal longitudinal 
systolic function of LV in ScH, which is first affected 
in LV systolic dysfunction (30,31). The parameter S/
TDI did not recover after treatment, but there was 
statistically significant correlation between TSH and 
S/TDI. More aggressive treatment for lowering TSH 
value may result in statistically significant changes in 
S/TDI. Completely identical results were shown in 
the study of Ilic and cols. (29). The average age in the 
study of Ilic and cols. (29) is similar to ours, but they 
analysed only women aged less than 45 years. Probably 
studies with a large number of patients involving only 
women in reproductive age are needed to confirm the 
impact of ScH on S wave derived from TDI. 
Results for MPI showed deterioration in global 
systolic and diastolic function of the LV in ScH, and 
its reversibility after thyroid replacement therapy. Our 
results were consistent with those from other clinical 
studies (24,25,29). The average values of TSH in 
those studies are similar to this study. There was no 
statistically significant correlation between TSH and 
MPI. The lack of correlation between TSH and MPI 
may be due to small changes in the value of MPI that 
occur at higher values of TSH.
Global longitudinal strain is considered more 
sensitive than EF in assessing LV global systolic function, 
especially when the EF is normal, in favour of subclinical 
LV dysfunction. Values of GLS in the control group 
and ScH group at baseline were within the normal 
range, but still with statistically significantly different 
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values in the ScH group. GLS significantly improved 
after the levothyroxine therapy. TSH significantly 
negatively correlated with GLS. Two studies examined 
GLS in ScH, and both of them showed results similar 
to ours (29,32).
The results from Doppler transmitral flow and 
velocities estimated by TDI showed changes in 
some parameters which are defined as parameters for 
diastolic function assessment. Although the values of 
some parameters were in the normal range, there is a 
statistically significant difference between the values 
of the control and ScH groups. This is shown by 
statistically significantly lower E/A ratio, and higher 
E/e’ sep. ratio in the ScH group compared to the 
control group.
After 5 months of euthyroid state, the E/A ratio did 
not increase significantly. In a study by Yazici and cols. 
(25) the E/A ratio was statistically significantly lower 
in patients with ScH compared to the control group. 
In the same study, the ratio increased significantly after 
6 months of euthyroid state and continued to increase 
after 12 months of euthyroid state. A study by Erkan and 
cols. (33) showed results similar to ours. Therefore, a 
longer euthyroid state or more aggressive treatment for 
lowering TSH may be required to achieve a statistically 
significant increase in the E/A ratio, after treatment. 
At the end of the study the average TSH value was 2.8 
± 2.6 mU/L. In the assessment of diastolic function 
the E/e’ sep. ratio is a more sensitive parameter than 
the E/e’ lat. ratio. A statistically significant difference 
in the E/e’ sep. ratio, but not in the E/e’ lat. Ratio, 
was found in other studies (24,28). Three patients in 
the ScH group had diastolic dysfunction, which was 
reversible after thyroid replacement therapy. Diastolic 
dysfunction is mainly attributed to ScH because other 
potential causes of diastolic dysfunction (hypertension, 
diabetes mellitus) were excluded in this study. 
Parameters which measured diastolic dysfunction can 
be applied to all patients with ScH and also to follow 
them during treatment. 
Statistically significant correlations between TSH 
and analysed parameters were weak (r < 0.5). The weak 
correlation coefficient may be due to higher TSH values 
at the end of the study. The r values were lower for 
correlations with diastolic parameters. Probably systolic 
parameters are more sensitive on L-T4 treatment, and 
diastolic parameters need a longer period of treatment.
Summarizing the results, ScH did not cause cardiac 
failure by itself, but thyroid substitution therapy 
improves some parameters of LV function. We analysed 
only patients with mild ScH, which means rapid 
detection of thyroid dysfunction. If ScH is detected 
later, according to the correlations, we expected 
worsening of LV parameters.
There are some limitations in this study. The design 
is not that of a blind or double-blind study which 
includes L-thyroxine and placebo. We followed the 
parameters of systolic and diastolic function, but we 
did not directly observe cardiovascular morbidity and 
mortality, which requires very long-term monitoring of 
patients. 
The advantages of the study compared to previous 
similar studies are the inclusion of young people with 
no risk factors for cardiovascular disease which can 
influence systolic and diastolic parameters, and the 
inclusion of patients with mild ScH. Thus, this study 
confirmed the benefit of levothyroxine treatment in 
patients with ScH with lower values of TSH. Today, 
when there is a lack of recommendations for treatment 
of mild ScH, this study moves the limits for initiation 
with treatment from the lower values of TSH. 
In conclusion, patients with ScH versus healthy 
individuals had subtle changes in certain parameters that 
indicate involvement of systolic and diastolic function of 
the LV in ScH. Although the values of the parameters 
were in normal range, they were significantly different 
compared to ScH and the control group at baseline, as 
well as to the ScH groups before and after treatment. 
The results of our study suggest that the patients with 
ScH deserve to be followed up during treatment. 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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